CoChat

Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization

Open access
Patel, Minal K., Bergeri, Isabel, Bresee, Joseph S., Cowling, Benjamin J., Crowcroft, Natasha S., Fahmy, Kamal, Hirve, Siddhivinayak, Kang, Gagandeep, Katz, Mark A., Lanata, Claudio F., L'Azou Jackson, Maïna, Joshi, Sudhir, Lipsitch, Marc, Mwenda, Jason M., Nogareda, Francisco, Orenstein, Walter A., Ortiz, Justin R., Pebody, Richard, Schrag, Stephanie J., Smith, Peter G., Srikantiah, Padmini, Subissi, Lorenzo, Valenciano, Marta, Vaughn, David W., Verani, Jennifer R., Wilder-Smith, Annelies, Feikin, Daniel R. · 2021 · Vaccine
Cited by 143

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints, resulting in emergency use authorization/listing for several vaccines. However, given the short duration of follow-up during the clinical trials, strict eligibility criteria, emerging variants of concern, and the changing epidemiology of the pandemic, many questions still remain unanswered regarding vaccine performance. Post-introduction vaccine effectiveness evaluations can help us to understand the vaccine's effect on reducing infection and disease when used in real-world conditions. They can also address important questions that were either not studied or were incompletely studied in the trials and that will inform evolving vaccine policy, including assessment of the duration of effectiveness; effectiveness in key subpopulations, such as the very old or immunocompromised; against severe disease and death due to COVID-19; against emerging SARS-CoV-2 variants of concern; and with different vaccination schedules, such as number of doses and varying dosing intervals. WHO convened an expert panel to develop interim best practice guidance for COVID-19 vaccine effectiveness evaluations. We present a summary of the interim guidance, including discussion of different study designs, priority outcomes to evaluate, potential biases, existing surveillance platforms that can be used, and recommendations for reporting results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2021.05.099

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 143

Metadata

Authors
Patel, M. K., Bergeri, I., Bresee, J. S., Cowling, B. J., Crowcroft, N. S., Fahmy, K., Hirve, S., Kang, G., Katz, M. A., Lanata, C. F., L'Azou Jackson, M., Joshi, S., Lipsitch, M., Mwenda, J. M., Nogareda, F., Orenstein, W. A., Ortiz, J. R., Pebody, R., Schrag, S. J., Smith, P. G., Srikantiah, P., Subissi, L., Valenciano, M., Vaughn, D. W., Verani, J. R., Wilder-Smith, A., & Feikin, D. R.
Venue
Vaccine
Publisher
Elsevier BV
Published
2021-07
Volume
39
Issue
30
Pages
4013-4024
ISSN
0264-410X (ISSN-L)
OpenAlex
W3172527002
Cited by
143
References
8
FWCI
9.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. https://app.cochat.ai/papers/10.1016/j.vaccine.2021.05.099
The paper
Patel, M. K., Bergeri, I., Bresee, J. S., Cowling, B. J., Crowcroft, N. S., Fahmy, K., Hirve, S., Kang, G., Katz, M. A., Lanata, C. F., L'Azou Jackson, M., Joshi, S., Lipsitch, M., Mwenda, J. M., Nogareda, F., Orenstein, W. A., Ortiz, J. R., Pebody, R., Schrag, S. J., . . . Feikin, D. R. (2021). Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. https://doi.org/10.1016/j.vaccine.2021.05.099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.